EATONTOWN, N.J., April 26, 2018 (GLOBE NEWSWIRE) — American CryoStem Corporation (OTC:CRYO), a leading strategic application developer, marketer, and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the company will be exhibiting at the American Society for Aesthetic Plastic Surgery (ASAPS): The Aesthetic Meeting 2018 in New York, NY at the Jacob J. Javits Convention Center, April 28 – 30. The Aesthetic Society, with more than 1,700 board certified aesthetic plastic surgeons, brings together a global gathering of innovators and experts to promote excellence in aesthetic plastic surgery.
The Aesthetic Meeting is the most important event, nationally and internationally, for clinical education and research in aesthetic surgery with over 3000 visitors to be expected to attend and over 200 leading exhibitors showcasing a wide range of products and services related to the aestheticsector.
The meeting is designed for plastic surgeons and nurses who want to offer the latest and best technologies and advancements to their clientele. With an increase in surgical procedures every year, and natural fat transfer procedures steadily increasing, plastic surgeons can see the latest in technology for removal and storage of adipose tissue. Data released in 2017 by the American Society of Plastic Surgeons (ASPS) reveals that Americans want to put their best face and body forward as their annual plastic surgery procedural statistics show a three percent growth in cosmetic procedures over the last year. From body fat reduction to harvesting fat to enhance other parts of the body, the data shows new cosmetic procedural trends related to the role of fat in body shaping. Fat grating procedures can more naturally counteract the loss of volume caused by aging, as that loss is replenished by a patient’s own tissue. So unwanted fat extracted from a patient’s abdomen can serve as a “natural filler” when it is transferred to more desirable areas of the body, such as the breast, buttock and face.
”Our participation in exhibiting our adipose tissue and stem cell services to the ASAPS has always been a successful event for the company. The event provides CRYO the ability to reach our targeted audience and develop relationships with aesthetic plastic surgeons in an environment where we can showcase our complete offerings,” said Anthony Dudzinski, Chief Operating Officer at American CryoStem Corporation.
American CryoStem Corporation representatives will be available to speak with all interested parties during the exhibiting days at The Aesthetic Meeting 2018 at booth number: 1034.
To schedule a private meeting with the company please email firstname.lastname@example.org or call 732-747-1007.
About American CryoStem Corporation
American CryoStem Corporation (OTC:CRYO); founded in 2008, is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, laboratory in New Jersey and licensed laboratories in Hong Kong, Bangkok, Thailand, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our platform and a developed product portfolio to create a global footprint of licensed laboratory affiliates, domestic and international physicians’ networks and research organizations who purchase tissue collection, processing and storage consumables from CRYO. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC’s) derived from adipose tissue that work in conjunction with our patented (non-animal) medium lines. The Company’s R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.